Emilie Jouanjus

Emilie Jouanjus

Auto-generated profile, based on publicly available information

Emilie Jouanjus

Faculty of Health University of Toulouse Toulouse France

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2014 in Journal of the American Heart Association
Verified
Journal Article
Open access
PDF file
EJEmilie Jouanjus
Emilie Jouanjus
MLMaryse Lapeyre-Mestre
Maryse Lapeyre-Mestre
JMJoelle Micallef
Joelle Micallef
TAThe French Association of the Regional Abuse
The French Association of the Regional Abuse
DCDependence Monitoring Centres (CEIP‐A) Working Group on Cannabis Complications*
Dependence Monitoring Centres (CEIP‐A) Working Group on Cannabis Complications*
Background: Cannabis is known to be associated with neuropsychiatric problems, but less is known about complications affecting other specified body systems. We report and analyze 35 recent remarkable cardiovascular complications following cannabis use. Methods and Results: In F rance, serious cases of abuse and dependence in response to the use of psychoactive substances must be reported to the national system of the F rench Addictovigilance Network. We identified all spontaneous reports of cardiovascular complications related to cannabis use collected by the F rench Addictovigilance Network from 2006 to 2010. We described the clinical characteristics of these cases and their evolution: 1.8% of all cannabis‐related reports (35/1979) were cardiovascular complications, with patients being mostly men (85.7%) and of an average age of 34.3 years. There were 22 cardiac complications (20 acute coronary syndromes), 10 peripheral complications (lower limb or juvenile arteriopathies and Buerger‐like diseases), and 3 cerebral complications (acute cerebral angiopathy, transient cortical blindness, and spasm of cerebral artery). In 9 cases, the event led to patient death. Conclusions: Increased reporting of cardiovascular complications related to cannabis and their extreme seriousness (with a death rate of 25.6%) indicate cannabis as a possible risk factor for cardiovascular disease in young adults, in line with previous findings. Given that cannabis is perceived to be harmless by the general public and that legalization of its use is debated, data concerning its danger must be widely disseminated. Practitioners should be aware that cannabis may be a potential triggering factor for cardiovascular complications in young people.

21 April 2017 in Current Atherosclerosis Reports
Verified
Journal Article
Closed access
PDF file
EJEmilie Jouanjus
Emilie Jouanjus
VRValentin Raymond
Valentin Raymond
MLMaryse Lapeyre-Mestre
Maryse Lapeyre-Mestre
VWValérie Wolff
Valérie Wolff

8 February 2019 in British Journal of Clinical Pharmacology
Verified
Journal Article
Open access
PDF file
DDDamien Driot
Damien Driot
EJEmilie Jouanjus
Emilie Jouanjus
SOStéphane Oustric
Stéphane Oustric
JDJulie DUPOUY
Julie DUPOUY
MLMaryse Lapeyre-Mestre
Maryse Lapeyre-Mestre
Aims: The aim of this study was to assess the use and factors associated with the misuse of gabapentin and pregabalin in the general French population, through a cohort study in the EGB (General Sample of Beneficiaries), a national representative sample of the French general population.Methods: New users of gabapentin and pregabalin were identified from June 2006 to December 2014, and new users of duloxetine served as control group. Misuse was defined as a use of higher daily doses than recommended. Cox proportional hazard regression models were performed to identify associated factors of misuse.Results: Misuse was more frequent in the 8692 new users of pregabalin (12.8%) than in the 1963 gabapentin (6.6%) or the 3214 duloxetine new users (9.7%) (P < 0.001). Factors associated with misuse were pregabalin (hazard ratio [HR] 1.48; 95% confidence interval [CI] [1.29–1.69]), age (HR[18–45] versus > 70 years 1.98 [1.70–2.31] and HR[58–70] versus > 70 years 1.25 [1.06–1.47]), multiple prescribers (HR2 or 3 versus 1 prescriber 1.29 [1.15–1.45]; HR4 or more versus 1 prescriber 1.54 [1.30–1.83]), cancer (1.28 [1.11–1.47]), multiple sclerosis (1.53 [1.07–2.18]), neuropathy (1.85 [1.19–2.89]), depression (1.26 [1.07–1.49]) and methadone (2.61 [1.16–5.84]). After this first episode of drug misuse, 11.6% of gabapentin and 10.7% of pregabalin misusers developed a primary addiction.Conclusion: In a cohort of new users, misuse is more likely to occur in new users of pregabalin, with different associated factors of misuse compared to gabapentin and duloxetine. Health professionals and prescribers must be aware of this misuse potential, which could lead to abuse and dependence.

1 May 2017 in Epilepsy & Behavior
Verified
Journal Article
Closed access
VWValérie Wolff
Valérie Wolff
EJEmilie Jouanjus
Emilie Jouanjus

22 November 2022 in Addiction
Verified
Journal Article
Open access
MRMarion Robert
Marion Robert
EJEmilie Jouanjus
Emilie Jouanjus
CKCharles Khouri
Charles Khouri
NSNathalie Fouilhé Sam‐Laï
Nathalie Fouilhé Sam‐Laï
BRBruno REVOL
Bruno REVOL
Background and Aims: The current opioid epidemic in the United States began 20 years ago and has become the leading cause of accidental deaths in the country. This crisis prompted us to explore trends in opioid abuse and dependence worldwide. We sought to identify other countries at high‐risk of opioid use disorders, using the World Health Organization's (WHO) pharmacovigilance database.Methods: We performed a disproportionality analysis using VigiBase, the WHO Global Individual Case Safety Report (ICSR) database. Five opioids used worldwide were included: oxycodone, fentanyl, morphine, tramadol, and codeine. We extracted all ICSRs associated with the drugs of interest, considered as suspect medication and recorded up until 5 June 2021, using the narrow Standardised MedDRA Query (SMQ) for drug abuse and dependence. Countries with at least one ICSR for each of the five opioids were retained. The relationship between the use of a drug (i.e. an opioid) and the occurrence of an adverse drug reaction (i.e. drug abuse and dependence) for each country was assessed by calculating the information component (IC) and its 99.9% CI [IC0005; IC9995], using a quasi‐Bayesian confidence propagation neural network (BCPNN). A hierarchical cluster analysis (Ward's method) of the IC0005 value for each of the five opioids was performed to identify subgroups of countries with similar reported risks of opioid abuse and dependence.Results: Among 21 countries, the optimal number of clusters was calculated to be four, each with a Jaccard index >0.5 (0.95, 0.78, 0.65 and 0.75, respectively). Six countries with the highest signals of drug abuse and dependence were identified in cluster 1, with significant CIs for the five opioids of interest (IC0005 > 0), ranging from 0.9 to 5.8 for the lower endpoint.Conclusions: There appear to be four distinct clusters of countries with similar opioid abuse and dependence profiles. The group with the highest reported risk for the opioids oxycodone, fentanyl, morphine, tramadol and codeine includes Australia, Canada, France, Germans, the United Kingdom and the United States.

13 February 2018 in Fundamental & Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
EJEmilie Jouanjus
Emilie Jouanjus
GGGrégory Guernec
Grégory Guernec
MLMaryse Lapeyre-Mestre
Maryse Lapeyre-Mestre
TNThe French Addictovigilance Network
The French Addictovigilance Network